Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929127 | 0.91 | ALDH1A1 (0.35) | KMT2AALDH1A1KDM4ECYP3A4 | |
| SCHEMBL5929210 | 0.90 | KDM4E (0.35) | KMT2AGAAALDH1A1KDM4EACHE | |
| SCHEMBL5929181 | 0.88 | KMT2A (0.34) | KMT2AALDH1A1KDM4EPOLBCYP3A4 | |
| SCHEMBL5928969 | 0.87 | HCRTR1 (0.37) | ALDH1A1KDM4E | |
| SCHEMBL5929030 | 0.85 | KDM4E (0.36) | KMT2AGAAALDH1A1KDM4EPOLB | |
| SCHEMBL5929059 | 0.83 | KDM4E (0.33) | KMT2AALDH1A1KDM4ENPSR1 | |
| SCHEMBL5929248 | 0.83 | KDM4E (0.33) | KMT2AALDH1A1KDM4ERECQL | |
| SCHEMBL5929000 | 0.81 | CYP3A4 (0.34) | KMT2AALDH1A1KDM4EPOLBCYP3A4 | |
| SCHEMBL5929310 | 0.75 | KMT2A (0.38) | KMT2AGAAALDH1A1KDM4E | |
| SCHEMBL5929061 | 0.72 | POLB (0.39) | KMT2AGAAALDH1A1KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | KMT2A 2955/4885GAA 4885/4885ALDH1A1 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.